Explore

Trendline Trendline
Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs
Trendline Trendline
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment
Trendline Trendline
IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer
Trendline Trendline
TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results